Therapeutic Efficacy of Astatine-211-Labeled Trastuzumab on Radioresistant SKOV-3 Tumors in Nude Mice

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 2, 2007, Pages 572-579

  Palm, Stig ^a   Bäck, Tom ^a   Claesson, Ingela ^a   Danielsson, Anna ^a   Elgqvist, Jörgen ^a   Frost, Sofia ^a   Hultborn, Ragnar ^a   Jensen, Holger ^b   Lindegren, Sture ^a   Jacobsson, Lars ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Rigshospitalet   (Denmark)

Author keywords

Particles; Astatine; Nude mice; Radioimmunotherapy; Trastuzumab

Indexed keywords

RADIOIMMUNOTHERAPY; TRASTUZUMAB;

ASTATINE; ONCOLOGY; RADIOLOGY; RADIOTHERAPY; RATS;

TUMORS;

ASTATINE 211; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; TRASTUZUMAB AT 211; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASTATINE; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; RADIATION TOLERANCE; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; RECEPTOR, ERBB-2;

EID: 34548478370     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.06.023     Document Type: Article

References (34)

1. Agarwal R., and Kaye S.B. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3 (2003) 502-516
2. Couturier O., Supiot S., Degraef-Mougin M., et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 32 (2005) 601-614
3. Andersson H., Elgqvist J., Horvath G., et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: An overview of results in an ovarian tumor model. Clin Cancer Res 9 Suppl. (2003) 3914S-3921S
4. Elgqvist J., Andersson H., Bäck T., et al. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. J Nucl Med 46 (2005) 1907-1915
5. 2: Therapeutic efficacy and myelotoxicity. Nucl Med Biol 33 (2006) 1065-1072
6. 2. Int J Radiat Oncol Biol Phys 66 (2006) 1228-1237
7. Elgqvist J., Andersson H., Bäck T., et al. α-Radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med 47 (2006) 1342-1350
8. 2 in therapy of ovarian cancer-Preliminary results from an ongoing phase I study. [Abstract]. Cancer Biother Radiopharm 21 (2006) 395
9. Petru E., Sevin B.U., and Gottlieb C. Radiosensitivity patterns of four human ovarian cancer cell lines in vitro. Gynecol Oncol 64 (1997) 490-492
10. Steren A., Sevin B.U., Perras J., et al. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 48 (1993) 252-258
11. Lindegren S., Back T., and Jensen H.J. Dry-distillation of astatine-211 from irradiated bismuth targets: A time-saving procedure with high recovery yields. Appl Radiat Isot 55 (2001) 157-160
12. Nahta R., and Esteva F.J. Herceptin: Mechanisms of action and resistance. Cancer Lett 232 (2006) 123-138
13. Lindegren S., Andersson H., Bäck T., et al. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate. Nucl Med Biol 28 (2001) 33-39
14. Lindmo T., Boven E., Cuttitta F., et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72 (1984) 77-89
15. Nishikawa Y., Yoshida Y., Kawahara K., et al. Establishment of a novel human ovarian cancer cell line with high anchorage-independent growth ability. Int J Oncol 23 (2003) 1679-1686
16. Palm S., Humm J.L., Rundqvist R., et al. Microdosimetry of astatine-211 single-cell irradiation: Role of daughter polonium-211 diffusion. Med Phys 31 (2004) 218-225
17. 60Co irradiation in nude mice. J Nucl Med 46 (2005) 464-471
18. Molina M.A., Codony-Servat J., Albanell J., et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61 (2001) 4744-4749
19. Borchardt P.E., Yuan R.R., Miederer M., et al. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 63 (2003) 5084-5090
20. Delord J.P., Allal C., Canal M., et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol 16 (2005) 1889-1897
21. Kim T.J., Lee J.W., Song S.Y., et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 94 (2006) 1678-1682
22. Wang H.Q., Altomare D.A., Skele K.L., et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24 (2005) 3574-3582
23. Helleman J., van Staveren I.L., Dinjens W.N., et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 6 (2006) 201
24. Lammerts van Bueren J.J., Bleeker W.K., Bogh H.O., et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: Implications for the mechanisms of action. Cancer Res 66 (2006) 7630-7638
25. Liang K., Lu Y., Jin W., et al. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2 (2003) 1113-1120
26. Bookman M.A., Darcy K.M., Clarke-Pearson D., et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21 (2003) 283-290
27. Song Y.J., Qu C.F., Rizvi S.M., et al. Cytotoxicity of PAI2, C595 and herceptin vectors labeled with the alpha-emitting radioisotope bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Lett 234 (2006) 176-183
28. Pack S.D., Alper O.M., Stromberg K., et al. Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Cancer Res 64 (2004) 789-794
29. Clynes R.A., Towers T.L., Presta L.G., et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 (2000) 443-446
30. 211At-labeled trastuzumab in human breast cancer cell lines: Effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol 33 (2006) 333-347
31. Grim J., Deshane J., Siegal G.P., et al. The level of erbB2 expression predicts sensitivity to the cytotoxic effects of an intracellular anti-erbB2 sFv. J Mol Med 76 (1998) 451-458
32. DeNardo G.L., Schlom J., Buchsbaum D.J., et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 94 (2002) 1332-1348
33. Shen S., Duan J., Meredith R.F., et al. Model prediction of treatment planning for dose-fractionated radioimmunotherapy. Cancer 94 (2002) 1264-1269
34. Bengala C., Zamagni C., Pedrazzoli P., et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: A retrospective study. Br J Cancer 94 (2006) 1016-1020